Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors

SAN FRANCISCO, Dec. 13, 2017 -- (Healthcare Sales & Marketing Network) -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatenin... Biopharmaceuticals, Personnel Audentes Therapeutics, gene therapy, X-Linked Myotubular Myopathy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news